Patient Conversations: Managing Patient Expectations Regarding Biosimilars

EP: 1.Utilizing Recently Approved Biosimilars in Clinical Practice

EP: 2.Transitioning to Biosimilars: Considerations for Providers and Payers

EP: 3.Navigating Challenges Associated with Biosimilars Across Various Disease States

EP: 4.Provider Acceptance Driving Confidence in Biosimilar Therapy

EP: 5.Decision-Making Process Surrounding Biosimilar Implementation

EP: 6.Biosimilar Administration Considerations Impacting Patient Experience

EP: 7.Initiating Biosimilar Treatment in Patients Without Previous Reference Biologic Experience

EP: 8.Switching Patients from Reference Product to Biosimilar

EP: 9.Defining Interchangeability and Switching in Biologics

EP: 10.Evolution of Auto-Substitution in Biosimilar Landscape

EP: 11.An Overview of Biosimilar Extrapolation During FDA Approval

EP: 12.Harnessing Indication-Specific Data on Biosimilars

EP: 13.Cost Savings Related to Biosimilars

EP: 14.Payers and PBMs Impacted by Biosimilar Integration

EP: 15.Payer Support Driving Lowering of Biosimilar-Related Health Care Costs

Now Viewing

EP: 16.Patient Conversations: Managing Patient Expectations Regarding Biosimilars

EP: 17.Key Points of Emphasis Regarding Biosimilar Integration

This is a video synopsis/summary of a panel discussion involving Ryan Haumschild, PharmD, MS, MBA; Alice B. Gottlieb, MD, PhD; Bincy Abraham, MD, MS; Jamie T. Brogan, APRN; and Vibeke Strand, MD.

Ryan Haumschild, PharmD, MS, MBA, asked Vibeke Strand, MD, how providers can manage patient expectations and address potential nocebo effects with biosimilars.

Vibeke Strand, MD, said shared decision-making and educating patients on biosimilars reduce nocebo effects. Patients should understand what biosimilars are and why they may be used. Multiple discussions over time and resources for additional questions allow patients to gain confidence. At the veteran health clinic, patients seem accepting of biosimilars with little pushback, perhaps owing to gratitude for care and respect for providers.

Ryan Haumschild, PharmD, MS, MBA, agreed patient education levels and capacity to understand biosimilars vary. Ensuring access and affordability enables positive outcomes from trials. He asked Jamie T. Brogan, APRN, about her strategies to enhance biosimilar access and affordability.

Jamie T. Brogan, APRN, uses an integrated specialty pharmacy for efficient prior authorization and access insights. She builds relationships with pharmaceutical resources for samples, assistance programs, and data to ease access. She provides educational materials, enrolls patients in company assistance programs, and proactively advises patients about potential switches to mitigate anxiety. Identifying coverage gaps and assistance programs maintains access and adherence.

Video synopsis is AI-generated and reviewed by AJMCÒ editorial staff.